| Summary: | Li-Zhe Zhong,1 Hong-Yan Xu,2 Zhong-Min Zhao,3 Guang-Mei Zhang,2 Feng-Wu Lin4 1Department of Cardiothoracic Surgery, Affiliated Hospital of Beihua University, Jilin, China; 2Department of Medical Oncology, The Second Hospital of Jilin, Jilin, China; 3Department of Pain, Jilin City Central Hospital, Jilin, China; 4Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China Objective: To evaluate the efficacy and safety of nedaplatin versus cisplatin in treating malignant pleural effusion (MPE) caused by cancers. Methods: The clinical data of 219 MPE patients treated from January 2013 to December 2016 were retrospectively reviewed. Intrapleural infusion with nedaplatin 80 mg/m2 (n=110) or with cisplatin 40 mg/m2 (n=109) were used as the treatment. Results: There was no significant difference in the overall response rate between the nedaplatin group (62.73%) and the cisplatin group (54.13%) (P=0.154). The nedaplatin group had significantly lower rates of gastrointestinal side effects and significantly less incidence of increased serum creatinine levels in comparison with the cisplatin group. The overall rate of toxicity in the nedaplatin group (40.00%) was significantly lower than in the cisplatin group (78.90%) (P<0.001). Conclusion: The efficacy of pleural perfusion with nedaplatin is noninferior to cisplatin in treating malignancy-induced MPE. Nedaplatin is associated with less toxicity in comparison with cisplatin. Keywords: malignant pleural effusion, pleural perfusion, platinum-based drug, toxicity
|
|---|
